[Anakinra for therapy of rheumatoid arthritis].
Tomoo
Takashi
T
Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba.
Sumida
Takayuki
T
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012795:Sialoglycoproteins / Q000009:adverse effects / Q000627:therapeutic use*
D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D017472:Receptors, Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D012795:Sialoglycoproteins; D000068800:Etanercept; D008727:Methotrexate